Docs call drugmakers ‘profiteers’ for costs of cancer meds

Eric Palmer Sanofi ($ SNY) is not very popular among its peers today. Its decision last year to halve the cost of its colon cancer drug Zaltrap in the face of high-profile criticism ...

AstraZeneca inks cancer deals with Bind Therapeutics, Horizon Discovery

Tracy Staton AstraZeneca ($ AZN) forged two oncology development deals on either side of the Atlantic. It teamed up with the U.K.'s Horizon Discovery on a program to target K-Ras ...

AstraZeneca works both sides of the Atlantic in forging new cancer drug deals

John Carroll While AstraZeneca’s busy business development team was fashioning a new discovery deal with Bind Therapeutics in Cambridge, MA, it was also polishing a pact in the ...

AstraZeneca and Boston biotech unite to blast cancer with a nanotech drug

Ryan McBride AstraZeneca has found another partner in an ongoing love fest with biotech startups. The drug giant ($ AZN), which is in the process of renovating its R&D wing, has ...

Epizyme hits the biotech IPO queue with rapid R&D plan for cancer drugs

Ryan McBride Epizyme wants to go public as the company plans on taking the fast lane to develop small molecules for genetically defined cancers. The Cambridge, MA-based biotech company ...

Abbott aids biotech Epizyme in matching epigenetic drug with cancer patients

Ryan McBride Abbott ($ ABT) plans to develop a companion diagnostic test for an experimental leukemia drug from the biotech startup Epizyme. The agreement follows the start of a Phase ...

Women at high risk urged to use breast cancer meds to prevent disease

Tracy Staton Two breast cancer drugs could get a boost from new expert advice. The U.S. Preventive Services Task Force now recommends that doctors offer the drugs–tamoxifen and ...

Pfizer breast cancer hopeful nabs FDA’s ‘breakthrough’ label

Tracy Staton Pfizer ($ PFE) won coveted "breakthrough" status from the FDA for its experimental breast cancer drug palbociclib after impressive interim results from a mid-stage ...

Syros Pharma snags $30M funding deal to target master switches of cancer genes

Ryan McBride With licenses to breaking discoveries from labs affiliated with MIT and Harvard, Syros Pharmaceuticals has raised $ 30 million in a Series A round of financing from top ...
Page 23 of 23« First...10...1920212223
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS